<DOC>
	<DOCNO>NCT02658968</DOCNO>
	<brief_summary>This study phase 1 , dose finding , open-label study patient relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) . This dose escalate study define maximum tolerable dose lutetium ( 177Lu ) -lilotomab satetraxetan ( Betalutin® ) DLBCL patient eligible autologous stem cell transplant . The study also assess safety toxicity , pharmacokinetics , biodistribution efficacy .</brief_summary>
	<brief_title>Study Betalutin Treatment Relapsed Refractory Non-Hodgkin Lymphoma ( LYMRIT-37-05 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Male female age ≥18 year . 2 . Histologically confirm DLBCL ( WHO classification ) . 3 . Received least one prior line therapy include immunochemotherapy . 4 . In first subsequent relapse , refractory last treatment ( define less complete metabolic response last treatment , within 6 month last treatment ) . 5 . Not suitable , decline high dose chemotherapy autologous stem cell transplantation ( ASCT ) . 6 . Presence radiographically measurable lymphadenopathy extranodal lymphoid malignancy ( least one objectively bidimensionally measurable ( nodal ) lesion ( &gt; 2 cm large dimension CT scan ) . 7 . Negative human antimurine antibody ( HAMA ) test . 8 . Life expectancy least 3 month . 9 . Bone marrow tumour infiltration &lt; 25 % tumour cell . 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 11 . Normal organ bone marrow function define : 1 . Absolute neutrophil count ≥1.5 x 109/L ; 2 . Platelet count ≥150 x 109/L ; 3 . Haemoglobin ≥9 g/dL ; 4 . Total bilirubin ≤1.5 x upper limit normal ( ULN ) ( except patient document Gilbert 's syndrome ) ; 5 . Liver enzymes : Aspartate transaminase ( AST ) ; Alanine transaminase ( ALT ) Alkaline phosphatase ( ALP ) ≤2.5 x ULN ( ≤5.0 x ULN liver involvement primary disease ) ; 6 . Adequate renal function demonstrate serum creatinine ≤1.5 mg/dL creatinine clearance &gt; 60 mL/min ; 7 . Normal coagulation parameter ( elevate international normalize ratio ( INR ) , prothrombin time activate partial thromboplastin time ( APTT ) ≤1.3 ULN range acceptable ) . 12 . Women childbearing potential must 1. understand study medication may teratogenic risk 2. negative serum pregnancy test screen Betalutin injection 3. commit continue abstinence heterosexual intercourse ( exclude periodic abstinence withdrawal method ) begin two acceptable method birth control PearlIndex ≤ 1 % . without interruption 4 week start study drug , throughout study drug therapy 12 month end study drug therapy , even amenorrhoea . Apart abstinence , acceptable method birth control : Combined ( estrogen progestogen contain ) hormonal contraception associate inhibition ovulation oral intravaginal transdermal Progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable Intrauterine device ( IUD ) Intrauterine hormonereleasing system ( IUS ) Bilateral tubal occlusion Vasectomised partner 13 . Male patient must agree use condom intercourse throughout study drug therapy follow 12 month . 14 . Ability give write , informed consent prior studyspecific screening procedure , understand consent may withdraw patient time without prejudice . 15 . Capable understand protocol requirement , willing able comply study protocol procedure , sign informed consent document . 16 . A negative Hepatitis B test ( HBsAg antiHBc ) negative HIV test screen 1 . Prior hematopoietic allogenic stem cell transplantation . 2 . Prior autologous stem cell transplantation . 3 . Previous total body irradiation , irradiation &gt; 25 % patient 's bone marrow . 4 . Prior antilymphoma therapy ( chemotherapy , immunotherapy investigational agent ) within 4 week prior start study treatment ( corticosteroid treatment dos ≤20 mg/day , GCSF GM CSF permit 2 week prior start study treatment. ) . Note : exclude pretreatment rituximab part study 5 . Patients receive investigational agent . 6 . Patients know suspected central nervous system involvement lymphoma . 7 . History previous treat cancer except follow : 1. adequately treated local basal cell squamous cell carcinoma skin ; 2. cervical carcinoma situ ; 3. superficial bladder cancer ; 4. localized prostate cancer undergo surveillance surgery ; 5. localise breast cancer treat surgery radiotherapy include systemic chemotherapy ; 6. adequately treated Stage 1 2 cancer currently complete remission ; 8 . Pregnant breastfeed woman . 9 . Exposure another CD37 target drug . 10 . Allergy X ray contrast agent . 11 . A known hypersensitivity rituximab , HH1 , Betalutin murine proteins excipient use rituximab , HH1 Betalutin . 12 . Has receive live attenuate vaccine within 30 day prior enrol study . 13 . Evidence severe uncontrolled systemic disease : 1. uncontrolled infection include evidence ongoing systemic bacterial , fungal , viral infection ( exclude viral upper respiratory tract infection ) time initiation study treatment ; 2. pulmonary condition e.g . unstable uncompensated respiratory disease 3. hepatic , renal neurological metabolic condition opinion investigator would compromise protocol objective . 4. psychiatric condition e.g . patient unlikely comply protocol , e.g . mental condition render patient unable understand nature , scope , possible consequence participate study 5. history erythema multiforme , toxic epidermal necrolysis StevensJohnson syndrome ; 6. cardiac condition , include history acute coronary syndrome ( include unstable angina ) class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system ; know uncontrolled arrhythmia ( except sinus arrhythmia ) past 24 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Lu-177</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Betalutin</keyword>
	<keyword>ARC</keyword>
	<keyword>Antibody Radionuclide Conjugate</keyword>
	<keyword>HH1</keyword>
	<keyword>Rituximab</keyword>
	<keyword>177Lu-DOTA-HH1</keyword>
	<keyword>Lilotomab</keyword>
	<keyword>Lutetium ( 177Lu ) -lilotomab satetraxetan</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Refractory DLBCL</keyword>
	<keyword>Relapsed DLBCL</keyword>
</DOC>